Clinical Trial Update: mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJA [NA]

View source ↗

Summary

A clinical trial compares three first-line regimens—mFOLFOX, mFOLFIRI, and FOLFPTX—for advanced gastric cancer and esophagogastric junction adenocarcinoma; the …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Adenocarcinoma of the Esophagogastric Junction
• Gastric Cancer

Drugs mentioned

• FOLFPTX
• mFOLFIRI
• mFOLFOX

Snippet

Sponsor: Fujian Cancer Hospital | Conditions: Advanced Gastric Cancer Adenocarcinoma of Esophagogastric Junction | NA | Status: UNKNOWN